Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series.
cholangiocarcinoma
cisplatin
gemcitabine
hepatocellular carcinoma
immunotherapy
liver transplantation
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
17 05 2022
17 05 2022
Historique:
received:
07
04
2022
revised:
01
05
2022
accepted:
06
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
The management of cholangiocarcinoma is continually reviewed on a current evidence basis to develop practice guidelines and consensus statements. However, the standardized treatment guidelines are still unclear for cholangiocarcinoma patients who are listed for liver transplantation. We aimed to validate and evaluate the potential efficacy of chemotherapy combination of Gemcitabine and Cisplatin as a neo-adjuvant treatment for cholangiocarcinoma patients before liver transplantation. In this prospective case series, patients with locally advanced, unresectable, hilar, or intrahepatic cholangiocarcinoma with no evidence of extrahepatic disease or vascular involvement were treated with a combination of neoadjuvant gemcitabine and cisplatin with no radiation. All patients included received chemotherapy prior to being listed for liver transplantation at a single cancer center according to an open-labeled, and center-approved clinical management protocol. The primary endpoints were the overall survival and recurrence-free survival after liver transplantation. Between 1 March 2016, and 15 March 2022, 10 patients (8 males and 2 females) with a median age of 62.71(interquartile range: 60.02-71.87) had a confirmed diagnosis of intrahepatic or hilar cholangiocarcinoma and underwent liver transplantation. Median days of neoadjuvant therapy for a given combination of gemcitabine and cisplatin were 181 (IRQ: 120-250). Nine patients (90%) were reported with no recurrence or metastasis, and only 1 patient had confirmed metastasis (10%); days for metastasis after transplantation were 612 for this patient. All patients received a combination of gemcitabine and cisplatin as neo-adjuvant while awaiting liver transplantation. The median days of follow-up were 851 (813-967). Overall survival was 100% (95% CI 100-100%) at both years one and two; 75% (95% CI 13-96%) at years three to five. One patient died at eight hundred and eighty-five days. No adverse events were reported after liver transplantation including the patient who was confirmed with recurrence. Our finding demonstrated that neo-adjuvant gemcitabine and cisplatin with no radiation prior to liver transplantation resulted in excellent outcomes for patients with cholangiocarcinoma.
Sections du résumé
BACKGROUND
The management of cholangiocarcinoma is continually reviewed on a current evidence basis to develop practice guidelines and consensus statements. However, the standardized treatment guidelines are still unclear for cholangiocarcinoma patients who are listed for liver transplantation. We aimed to validate and evaluate the potential efficacy of chemotherapy combination of Gemcitabine and Cisplatin as a neo-adjuvant treatment for cholangiocarcinoma patients before liver transplantation.
METHODS
In this prospective case series, patients with locally advanced, unresectable, hilar, or intrahepatic cholangiocarcinoma with no evidence of extrahepatic disease or vascular involvement were treated with a combination of neoadjuvant gemcitabine and cisplatin with no radiation. All patients included received chemotherapy prior to being listed for liver transplantation at a single cancer center according to an open-labeled, and center-approved clinical management protocol. The primary endpoints were the overall survival and recurrence-free survival after liver transplantation.
RESULTS
Between 1 March 2016, and 15 March 2022, 10 patients (8 males and 2 females) with a median age of 62.71(interquartile range: 60.02-71.87) had a confirmed diagnosis of intrahepatic or hilar cholangiocarcinoma and underwent liver transplantation. Median days of neoadjuvant therapy for a given combination of gemcitabine and cisplatin were 181 (IRQ: 120-250). Nine patients (90%) were reported with no recurrence or metastasis, and only 1 patient had confirmed metastasis (10%); days for metastasis after transplantation were 612 for this patient. All patients received a combination of gemcitabine and cisplatin as neo-adjuvant while awaiting liver transplantation. The median days of follow-up were 851 (813-967). Overall survival was 100% (95% CI 100-100%) at both years one and two; 75% (95% CI 13-96%) at years three to five. One patient died at eight hundred and eighty-five days. No adverse events were reported after liver transplantation including the patient who was confirmed with recurrence.
CONCLUSIONS
Our finding demonstrated that neo-adjuvant gemcitabine and cisplatin with no radiation prior to liver transplantation resulted in excellent outcomes for patients with cholangiocarcinoma.
Identifiants
pubmed: 35621680
pii: curroncol29050290
doi: 10.3390/curroncol29050290
pmc: PMC9139862
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
3585-3594Références
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Ann Surg. 2004 Feb;239(2):265-71
pubmed: 14745336
Am J Surg Pathol. 2016 Aug;40(8):1021-30
pubmed: 27259014
Am J Surg. 1993 Dec;166(6):768-71; discussion 771-2
pubmed: 8273866
Ann Surg. 2008 Jul;248(1):84-96
pubmed: 18580211
Therap Adv Gastroenterol. 2017 Jun;10(6):507-520
pubmed: 28567120
Langenbecks Arch Surg. 2013 Jan;398(1):71-7
pubmed: 23053456
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638395
Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):189-200
pubmed: 21460876
Arch Surg. 2011 Jun;146(6):683-9
pubmed: 21690444
Ann Surg. 2014 May;259(5):944-52
pubmed: 24441817
J Natl Compr Canc Netw. 2009 Apr;7(4):350-91
pubmed: 19406039
Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61
pubmed: 16135931
Hepatology. 2016 Oct;64(4):1178-88
pubmed: 27481548
J Clin Med. 2022 Apr 06;11(7):
pubmed: 35407665
Eur Surg Res. 2011;47(4):218-21
pubmed: 22041581
Hepatology. 2017 May;65(5):1777-1778
pubmed: 27997682
Cancers (Basel). 2022 Jan 31;14(3):
pubmed: 35159010
Cancers (Basel). 2021 Jul 02;13(13):
pubmed: 34283065
World J Surg. 1995 Nov-Dec;19(6):807-13
pubmed: 8553670
Surgery. 2013 Jun;153(6):811-8
pubmed: 23499016
Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14
pubmed: 22504095
HPB (Oxford). 2015 Apr;17(4):344-51
pubmed: 25395176
Cancers (Basel). 2022 Mar 30;14(7):
pubmed: 35406533
Am J Transplant. 2002 Sep;2(8):774-9
pubmed: 12243499
Br J Cancer. 2009 Aug 18;101(4):621-7
pubmed: 19672264
J Gastrointest Oncol. 2016 Apr;7(2):248-54
pubmed: 27034793
JAMA Surg. 2015 Jun;150(6):538-45
pubmed: 25831462
Curr Treat Options Oncol. 2016 Nov;17(11):58
pubmed: 27658789
Transplantation. 2000 Apr 27;69(8):1633-7
pubmed: 10836374
Curr Opin Gastroenterol. 2012 May;28(3):258-65
pubmed: 22333563
J Clin Oncol. 2013 Mar 20;31(9):1188-95
pubmed: 23358969
Cancers (Basel). 2022 Jan 27;14(3):
pubmed: 35158918